Canadian Cancer Trials Group Bulletins


Recent Publications

IND.187 - A Phase I Study Of AZD2281 In Combination With Irinotecan In Patients With Locally Advanced or Metastatic Incurable Colorectal Cancer

This phase I study was conducted to evaluate the safety and tolerability of olaparib in combination with irinotecan. Patients with advanced colorectal cancer whose disease progressed after at least one systemic therapy regimen were enrolled. The authors conclude that olaparib can be combined with irinotecan if administered intermittently. Both olaparib and irinotecan required significant dose reductions. The lack of anti-tumour efficacy observed in this trial makes this combination of little interest for further clinical development.

Chen EX, Jonker DJ, Siu LL, McKeever K, Keller D, Wells J, Hagerman L, Seymour L. A Phase I study of olaparib and irinotecan in patients with colorectal cancer: Canadian Cancer Trials Group IND 187 (ONLINE). Invest New Drugs 1-8, 2016.

IND.197 - A Phase II Study of Foretinib in Patients with Estrogen Receptor (ER), Progesterone Receptor (PR), and Human Epidermal Growth Factor Receptor 2 (HER2) Negative, Recurrent/Metastatic Breast Cancer

IND.197 was a single-arm, non-blinded multicenter phase II trial to investigate the efficacy of continuous single-agent foretinib in patients with incurable triple-negative breast cancer (TNBC). Primary endpoints were objective response and early progression rates per RECIST 1.1. Although CCTG IND.197 did not meet its primary endpoint, the observation of a clinical benefit rate of 46% in this cTNBC population suggests that foretinib may have clinical activity as a single, non-cytotoxic agent in TNBC

Rayson D, Lupichuk S, Potvin K, Dent S, Shenkier T, Dhesy-Thind S, Ellard SL, Prady C, Salim M, Farmer P, Allo G, Tsao MS, Allan A, Ludkovski O, Bonomi M, Tu D, Hagerman L, Goodwin R, Eisenhauer E, Bradbury P. Canadian Cancer Trials Group IND197: a phase II study of foretinib in patients with estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2-negative recurrent or metastatic breast cancer (ONLINE). Breast Cancer Res Treat 1-8, 2016.